In this regard, the literature, based on numerous independent and diverse observations, highlights a clear role for GIPR activation in the development of obesity, grounding the concept of GIPR antagonism as a potential approach to alleviate insulin resistance and excessive weight gain (Irwin et al. 2020). The gene discussed is INS; the disease is obesity disorder.